SCHEDULE: BVF Group Discloses 5.1% Stake in Compass Therapeutics
Beneficial Ownership Disclosure
A group of entities led by Mark N. Lampert, including Biotechnology Value Fund L.P., has reported a collective beneficial ownership of 5.1% in Compass Therapeutics, Inc.
Summary
- Biotechnology Value Fund L.P. (BVF) and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, have filed a Schedule 13G.
- The filing discloses beneficial ownership of Common Stock, $0.0001 par value per share, of Compass Therapeutics, Inc.
- As of October 29, 2025, the aggregate beneficial ownership by BVF, BVF2, and Trading Fund OS, and indirectly by their respective general partners and controlling persons, totals 8,750,000 shares.
- This aggregate amount represents approximately 5.1% of the outstanding shares of Compass Therapeutics, Inc., based on 171,572,498 shares outstanding as of August 13, 2025.
- The reporting persons share both voting and dispositive power over these 8,750,000 shares.
- The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine disclosure of beneficial ownership by an institutional investor group and does not contain specific positive or negative operational or financial news for the issuer.
Future Outlook
No forward-looking statements or guidance regarding Compass Therapeutics, Inc.'s operations or financial performance are provided in this beneficial ownership disclosure.
Industry Context
This filing represents a routine disclosure of a significant institutional ownership stake in a biotechnology company. Such disclosures provide transparency regarding major investors but do not inherently reflect on the company's operational performance or strategic direction.
Stakeholder Impact
- Shareholders are informed of a significant institutional investor's stake in Compass Therapeutics, Inc., which may influence market perception of the company's investor base.
Key Dates
| Date | Description |
|---|---|
| 10/22/2025 | Date of event which required the filing of this statement |
| 10/29/2025 | Date of Joint Filing Agreement and filing date of Schedule 13G |
Keywords
Compass Therapeutics, CTXR, Biotechnology Value Fund, BVF, Mark N. Lampert, Schedule 13G, beneficial ownership, institutional investor, biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.